Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lankan ancestry: In vitro expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X

Ikuko Isshiki, Remi Favier, Takanori Moriki, Toshihiro Uchida, Hiroaki Ishihara, Patrick Van Dreden, Mitsuru Murata, Yasuo Ikeda

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We investigated a new family with cross-reactive material-positive factor X (FX) deficiency. The proband was an 11-year-old French girl from Sri Lanka with a tendency towards severe bleeding. The FX antigen level was 67%, although the activity with extrinsic pathway was 1 U/dl. The complete nucleotide sequences of all exons and exon/ intron junctions of the patient's genomic DNA revealed a homozygous G → A substitution in exon 8, which would result in replacement of Gly366 with Ser. The proband is the first reported case of homozygote for the FX Gly366Ser mutation. Heterozygosity for Gly366Ser substitution was previously reported in a Japanese patient (FX Nagoya 2). We studied the functional consequences by expressing mutant FX Gly366Ser protein in HEK293 cells. FX Gly366Ser was secreted into the culture media at levels similar to wild-type FX; however, mutant FX activities were only 0.04, 1.05, and 0.75% of wild-type FX upon activation by the extrinsic system, the intrinsic system, and Russell's viper venom, respectively. Moreover, the activity of FX Gly366Ser was undetectable when analyzed with chromogenic-activated FX and thrombin generation assays. These data suggest that the Gly366Ser substitution would cause a major defect in function of the FX molecule.

Original languageEnglish
Pages (from-to)9-16
Number of pages8
JournalBlood Coagulation and Fibrinolysis
Volume16
Issue number1
DOIs
Publication statusPublished - 2005 Jan

Fingerprint

Factor X Deficiency
Factor X
Exons
Russell's Viper
Viper Venoms
In Vitro Techniques
Sri Lanka
Factor Xa
HEK293 Cells
Homozygote
Thrombin
Introns
Culture Media

Keywords

  • Cross-reactive material-positive factor X deficiency
  • Factor X Nagoya 2
  • Gly366Ser factor X mutant

ASJC Scopus subject areas

  • Hematology

Cite this

Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lankan ancestry : In vitro expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X. / Isshiki, Ikuko; Favier, Remi; Moriki, Takanori; Uchida, Toshihiro; Ishihara, Hiroaki; Van Dreden, Patrick; Murata, Mitsuru; Ikeda, Yasuo.

In: Blood Coagulation and Fibrinolysis, Vol. 16, No. 1, 01.2005, p. 9-16.

Research output: Contribution to journalArticle

@article{2d5bc58eaeda4cd5b0bb315023464479,
title = "Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lankan ancestry: In vitro expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X",
abstract = "We investigated a new family with cross-reactive material-positive factor X (FX) deficiency. The proband was an 11-year-old French girl from Sri Lanka with a tendency towards severe bleeding. The FX antigen level was 67{\%}, although the activity with extrinsic pathway was 1 U/dl. The complete nucleotide sequences of all exons and exon/ intron junctions of the patient's genomic DNA revealed a homozygous G → A substitution in exon 8, which would result in replacement of Gly366 with Ser. The proband is the first reported case of homozygote for the FX Gly366Ser mutation. Heterozygosity for Gly366Ser substitution was previously reported in a Japanese patient (FX Nagoya 2). We studied the functional consequences by expressing mutant FX Gly366Ser protein in HEK293 cells. FX Gly366Ser was secreted into the culture media at levels similar to wild-type FX; however, mutant FX activities were only 0.04, 1.05, and 0.75{\%} of wild-type FX upon activation by the extrinsic system, the intrinsic system, and Russell's viper venom, respectively. Moreover, the activity of FX Gly366Ser was undetectable when analyzed with chromogenic-activated FX and thrombin generation assays. These data suggest that the Gly366Ser substitution would cause a major defect in function of the FX molecule.",
keywords = "Cross-reactive material-positive factor X deficiency, Factor X Nagoya 2, Gly366Ser factor X mutant",
author = "Ikuko Isshiki and Remi Favier and Takanori Moriki and Toshihiro Uchida and Hiroaki Ishihara and {Van Dreden}, Patrick and Mitsuru Murata and Yasuo Ikeda",
year = "2005",
month = "1",
doi = "10.1097/00001721-200501000-00002",
language = "English",
volume = "16",
pages = "9--16",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lankan ancestry

T2 - In vitro expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X

AU - Isshiki, Ikuko

AU - Favier, Remi

AU - Moriki, Takanori

AU - Uchida, Toshihiro

AU - Ishihara, Hiroaki

AU - Van Dreden, Patrick

AU - Murata, Mitsuru

AU - Ikeda, Yasuo

PY - 2005/1

Y1 - 2005/1

N2 - We investigated a new family with cross-reactive material-positive factor X (FX) deficiency. The proband was an 11-year-old French girl from Sri Lanka with a tendency towards severe bleeding. The FX antigen level was 67%, although the activity with extrinsic pathway was 1 U/dl. The complete nucleotide sequences of all exons and exon/ intron junctions of the patient's genomic DNA revealed a homozygous G → A substitution in exon 8, which would result in replacement of Gly366 with Ser. The proband is the first reported case of homozygote for the FX Gly366Ser mutation. Heterozygosity for Gly366Ser substitution was previously reported in a Japanese patient (FX Nagoya 2). We studied the functional consequences by expressing mutant FX Gly366Ser protein in HEK293 cells. FX Gly366Ser was secreted into the culture media at levels similar to wild-type FX; however, mutant FX activities were only 0.04, 1.05, and 0.75% of wild-type FX upon activation by the extrinsic system, the intrinsic system, and Russell's viper venom, respectively. Moreover, the activity of FX Gly366Ser was undetectable when analyzed with chromogenic-activated FX and thrombin generation assays. These data suggest that the Gly366Ser substitution would cause a major defect in function of the FX molecule.

AB - We investigated a new family with cross-reactive material-positive factor X (FX) deficiency. The proband was an 11-year-old French girl from Sri Lanka with a tendency towards severe bleeding. The FX antigen level was 67%, although the activity with extrinsic pathway was 1 U/dl. The complete nucleotide sequences of all exons and exon/ intron junctions of the patient's genomic DNA revealed a homozygous G → A substitution in exon 8, which would result in replacement of Gly366 with Ser. The proband is the first reported case of homozygote for the FX Gly366Ser mutation. Heterozygosity for Gly366Ser substitution was previously reported in a Japanese patient (FX Nagoya 2). We studied the functional consequences by expressing mutant FX Gly366Ser protein in HEK293 cells. FX Gly366Ser was secreted into the culture media at levels similar to wild-type FX; however, mutant FX activities were only 0.04, 1.05, and 0.75% of wild-type FX upon activation by the extrinsic system, the intrinsic system, and Russell's viper venom, respectively. Moreover, the activity of FX Gly366Ser was undetectable when analyzed with chromogenic-activated FX and thrombin generation assays. These data suggest that the Gly366Ser substitution would cause a major defect in function of the FX molecule.

KW - Cross-reactive material-positive factor X deficiency

KW - Factor X Nagoya 2

KW - Gly366Ser factor X mutant

UR - http://www.scopus.com/inward/record.url?scp=12544250870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12544250870&partnerID=8YFLogxK

U2 - 10.1097/00001721-200501000-00002

DO - 10.1097/00001721-200501000-00002

M3 - Article

C2 - 15650540

AN - SCOPUS:12544250870

VL - 16

SP - 9

EP - 16

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 1

ER -